Teriparatide — Membership Pricing

Other medications in Bone Health

• Zoledronic Acid
• Abaloparatide
• Calcitonin
• Calcium Carbonate
• Denosumab
• Etidronate
• Romosozumab

About Teriparatide

Teriparatide is a powerful medication often prescribed for individuals with severe osteoporosis, helping to stimulate new bone formation and reduce fracture risk. Understanding its role is crucial for those managing this condition. At TheDrugClub, we understand the financial burden of essential medications, and our membership program is designed to help you access significant savings on prescriptions like teriparatide.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Teriparatide is approved for (FDA label)

FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.

Source: Read the full FDA label on DailyMed. Label effective date: August 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Teriparatide (FDA label)

Injection: 560 mcg/2.24 mL (250 mcg/mL) clear, colorless solution in a single-patient-use prefilled delivery device (pen) intended to deliver 28 daily doses of 20 mcg. Injection: 560 mcg/2.24 mL (250 mcg/mL) in a single-patient-use prefilled delivery device (pen) intended to deliver 28 daily doses of 20 mcg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: aae667c5-381f-4f92-93df-2ed6158d07b0. SPL document ID: d099f168-02f9-4a89-af68-f3ff6d4418e4. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Teriparatide (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [ see Warnings and Precautions ( 5.1 ) ] Osteosarcoma [ see Warnings and Precautions ( 5.2 ) ] Hypercalcemia and Cutaneous Calcification [ see Warnings and Precautions ( 5.3 ) ] Risk of Urolithiasis [ see Warnings and Precautions ( 5.4 ) ] Orthostatic Hypotension [ see Warnings and Precautions ( 5.5 ) ] Risk of Digoxin Toxicity [ see Warnings and Precautions ( 5.6 ) ] Most common adverse reactions (>10%) include: arthralgia, pain, and nausea ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: aae667c5-381f-4f92-93df-2ed6158d07b0. SPL document ID: d099f168-02f9-4a89-af68-f3ff6d4418e4. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Teriparatide (FDA label)

FORTEO is contraindicated in patients with a history of severe hypersensitivity to teriparatide or any of the inactive ingredients of FORTEO. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6.2 )] . Patients with severe hypersensitivity to teriparatide or any of the inactive ingredients of FORTEO( 4 )

Source: FDA prescribing information (DailyMed). Set ID: aae667c5-381f-4f92-93df-2ed6158d07b0. SPL document ID: d099f168-02f9-4a89-af68-f3ff6d4418e4. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Teriparatide (FDA label)

Hypersensitivity Reactions : Anaphylaxis, angioedema, and urticaria have been reported in patients treated with parathyroid hormone analogs, including FORTEO. If signs or symptoms of a hypersensitivity reaction occur, discontinue treatment with FORTEO, initiate supportive care, and monitor until signs and symptoms resolve. Discontinue FORTEO permanently in patients with a severe hypersensitivity reaction to FORTEO. ( 5.1 ) Osteosarcoma : Avoid use in patients with increased risk of osteosarcoma including patients with open epiphyses, metabolic bone diseases including Paget's disease, bone metastases or history of skeletal malignancies, prior external beam or implant radiation therapy involving the skeleton, and hereditary disorders predisposing to osteosarcoma. ( 5.2 ) Hypercalcemia and Cutaneous Calcification : Avoid in patients known to have an underlying hypercalcemic disorder.

Source: FDA prescribing information (DailyMed). Set ID: aae667c5-381f-4f92-93df-2ed6158d07b0. SPL document ID: d099f168-02f9-4a89-af68-f3ff6d4418e4. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Teriparatide (FDA label)

Digoxin: Transient hypercalcemia may predispose patients to digitalis toxicity ( 5.6 , 7.1 ) 7.1 Digoxin Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. FORTEO may transiently increase serum calcium. Consider the potential onset of signs and symptoms of digitalis toxicity when FORTEO is used in patients receiving digoxin [see Warnings and Precaution ( 5.6 ) and Clinical Pharmacology ( 12.3 )] .

Source: FDA prescribing information (DailyMed). Set ID: aae667c5-381f-4f92-93df-2ed6158d07b0. SPL document ID: d099f168-02f9-4a89-af68-f3ff6d4418e4. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.